"Company files patent for treatment of chemotherapy-induced accelerated aging as a step towards treatment of other causes of aging."
Immorta Bio has recently filed a patent for a novel treatment addressing chemotherapy-induced accelerated aging using exosome technology. This innovative approach aims to mitigate the premature aging effects often experienced by cancer patients undergoing chemotherapy, such as fatigue, cognitive decline, and decreased organ function. By harnessing the regenerative potential of exosomes—small extracellular vesicles that facilitate cell communication and repair—Immorta Bio seeks to rejuvenate damaged tissues and counteract the adverse effects of chemotherapy. This development marks a significant step toward broader applications in combating various aging-related conditions.